ELAC2 Antibody | 22-724

ELAC2 Antibody | 22-724 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1-270 of human ELAC2 (NP_776065.1) .

Research Area: Cancer, Cell Cycle

Tested Application: WB, IHC, IF

Application: WB: 1:500 - 1:2000
IHC: 1:50 - 1:200
IF: 1:50 - 1:100

Specificiy: N/A

Positive Control 1: MCF7

Positive Control 2: NCI-H460

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Observed: 105kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: ELAC2, ElaC (E. coli) homolog 2, ElaC homolog 2 (E. coli) , ELC2, ElaC homolog protein 2, HPC2, RNase Z 2, Ribonuclease Z 2, TRNA 3 endonuclease 2, TRNase Z (long form) , TRNase Z 2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: The protein encoded by this gene has a C-terminal domain with tRNA 3' processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1) , and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene.